
NBRV
Healthcare · Biotechnology & Medical Research · $4.5M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2022
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 4 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Mar 27, 2024 | Time not confirmed | -1.33 | 0.00 | +100.0% |
| Nov 9, 2023 | Time not confirmed | -1.95 | 0.00 | +100.0% |
| Aug 10, 2023 | After the close | -2.30 | 0.00 | +100.0% |
| Apr 17, 2023 | After the close | -3.37 | -2.72 | +19.4% |
| Mar 16, 2023 | Time not confirmed | -4.03 | -4.15 | -3.0% |
| Nov 10, 2022 | After the close | -4.03 | -4.21 | -4.5% |
| Aug 3, 2022 | After the close | -5.00 | -4.50 | +10.0% |
| May 5, 2022 | After the close | -4.75 | -5.00 | -5.3% |
| Mar 29, 2022 | After the close | -4.75 | -6.00 | -26.3% |
| Nov 9, 2021 | After the close | -6.12 | -0.52 | +91.5% |
| Aug 5, 2021 | After the close | -8.67 | -7.25 | +16.4% |
| May 6, 2021 | After the close | -16.75 | -13.25 | +20.9% |
| Mar 11, 2021 | After the close | -23.75 |
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also…
| -27.75 |
| -16.8% |
| Nov 5, 2020 | After the close | -24.37 | -22.50 | +7.7% |
| Aug 6, 2020 | After the close | -40.00 | -35.00 | +12.5% |
| May 11, 2020 | After the close | -66.00 | -62.50 | +5.3% |
| Mar 12, 2020 | After the close | -83.00 | -72.50 | +12.7% |
| Nov 12, 2019 | After the close | -70.62 | -60.00 | +15.0% |
| Aug 8, 2019 | Before the open | -83.75 | -75.00 | +10.4% |
| May 10, 2019 | Before the open | -80.50 | -72.50 | +9.9% |
| Mar 12, 2019 | Before the open | -81.25 | -102.50 | -26.2% |
| Nov 6, 2018 | Before the open | -73.50 | -90.00 | -22.4% |
| Aug 9, 2018 | Before the open | -119.64 | -110.00 | +8.1% |
| May 8, 2018 | Before the open | -147.00 | -90.00 | +38.8% |
| Mar 16, 2018 | Before the open | -141.67 | -152.50 | -7.6% |